You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

METHOTREXATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Methotrexate patents expire, and what generic alternatives are available?

Methotrexate is a drug marketed by Accord Hlthcare, Hospira, Fresenius Kabi Usa, Abraxis Pharm, Hikma, Norbrook, Pharmachemie Usa, Epic Pharma Llc, Alembic, Amneal Pharms, Barr, Daito, Duramed Pharms Barr, Elite Labs Inc, Eugia Pharma, Lotus Pharm Co Ltd, Mylan, Strides Pharma, Sun Pharm, Zydus Pharms, Eugia Pharma Speclts, Pharmachemie Bv, Rising, Sagent Pharms Inc, and Sandoz. and is included in forty-two NDAs.

The generic ingredient in METHOTREXATE is calcium chloride; dextrose; glutathione disulfide; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate. There are two hundred and eighty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the calcium chloride; dextrose; glutathione disulfide; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for METHOTREXATE?
  • What are the global sales for METHOTREXATE?
  • What is Average Wholesale Price for METHOTREXATE?
Drug patent expirations by year for METHOTREXATE
Drug Prices for METHOTREXATE

See drug prices for METHOTREXATE

Drug Sales Revenue Trends for METHOTREXATE

See drug sales revenues for METHOTREXATE

Recent Clinical Trials for METHOTREXATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Alexion Pharmaceuticals, Inc.Phase 4
Syndax PharmaceuticalsPhase 1
University of California, Los AngelesPhase 1

See all METHOTREXATE clinical trials

US Patents and Regulatory Information for METHOTREXATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare METHOTREXATE SODIUM PRESERVATIVE FREE methotrexate sodium INJECTABLE;INJECTION 040716-001 Apr 30, 2007 AP RX No Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Duramed Pharms Barr METHOTREXATE SODIUM methotrexate sodium TABLET;ORAL 040233-001 Jun 17, 1999 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Hikma METHOTREXATE SODIUM PRESERVATIVE FREE methotrexate sodium INJECTABLE;INJECTION 089340-001 Sep 16, 1986 AP RX No Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for METHOTREXATE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Nordic Group B.V. Nordimet methotrexate EMEA/H/C/003983
Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.
Authorised no no no 2016-08-18
Therakind (Europe) Limited Jylamvo methotrexate EMEA/H/C/003756
In rheumatological and dermatological diseasesActive rheumatoid arthritis in adult patients.Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate.Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.In oncologyMaintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over.
Authorised no no no 2017-03-29
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

METHOTREXATE Market Analysis and Financial Projection Experimental

Methotrexate Drug Market: Dynamics and Financial Trajectory

Market Overview

The methotrexate drug market is poised for significant growth over the next decade, driven by several key factors. Here’s a detailed look at the market dynamics and financial trajectory of methotrexate.

Market Size and Growth Projections

  • The methotrexate drug market was valued at approximately USD 621.3 million in 2024 and is projected to reach USD 1,058 million by 2034, growing at a Compound Annual Growth Rate (CAGR) of 5.5% during this period[1].
  • Another report estimates the market size to be around USD 590.4 million in 2023, with a forecasted growth to USD 776.5 million by 2031 at a CAGR of 3.1%[4].

Key Drivers of Growth

Increasing Prevalence of Target Diseases

The global burden of diseases such as rheumatoid arthritis, psoriasis, and various types of cancer is on the rise. This increasing prevalence is a major driver for the demand of methotrexate, which is widely used to treat these conditions[5].

Technological Advancements and Personalized Medicine

Advancements in medication delivery systems and formulations are improving patient outcomes and adherence. The demand for personalized medicine is also fostering the growth of the methotrexate market[3].

Aging Population and Healthcare Expenditure

An aging population is more prone to cancer and autoimmune diseases, which in turn increases the demand for methotrexate. Rising healthcare expenditure, especially in developing nations, is also contributing to the market growth[4].

Research and Development

Ongoing research and development activities aimed at discovering new therapeutic applications and creating innovative formulations or combination medicines are expected to propel the market forward[5].

Market Segmentation

Indication

  • The methotrexate market is segmented based on indications such as psoriasis, rheumatoid arthritis, cancer, and other diseases. The cancer segment is forecasted to show robust growth, reaching USD 263.4 million by 2032[3].
  • Rheumatoid arthritis is another significant segment, expected to register a CAGR of 5.3% from 2024 to 2034[1].

Drug Type

  • The market is bifurcated into branded and generic methotrexate drugs. The branded segment accounted for USD 346.6 million in 2023[3].

Drug Form

  • Methotrexate is available in various forms such as tablets, liquids, and injectables. The tablet segment is forecasted to reach USD 375.5 million by 2032[3].

Route of Administration

  • The market is segmented based on the route of administration, including oral, subcutaneous, intramuscular, and intravenous. The oral segment accounted for USD 268.6 million in 2023[3].

Distribution Channel

  • The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies accounted for USD 248.6 million in 2023[3].

Regional Analysis

United States

  • The U.S. methotrexate market is expected to grow at a CAGR of 5.7% from 2024 to 2034. Rising concerns about cancer and autoimmune diseases, along with expanding healthcare expenditure and a shift toward value-based care, are driving this growth[1].

China

  • The Chinese market is projected to grow at a CAGR of 5.9% during the forecast period. This growth is attributed to increasing healthcare expenditure and technological advancements[1].

Japan and South Korea

  • Japan and South Korea are also expected to witness significant growth, with Japan’s market growing at a CAGR of 7.0% and South Korea’s at 6.9% from 2024 to 2034[1].

Europe

  • The UK and other European countries are expected to experience promising growth from 2024 to 2032, driven by increased research and development activities and the presence of refined medical facilities[3].

Financial Performance and Investment

Revenue and Net Income

  • Companies in the methotrexate market are generating significant revenues. For example, Cumberland Pharmaceuticals reported net revenues of $8.1 million for the third quarter of 2021, with specific products like Kristalose® and Vibativ® contributing substantially to these revenues[2].

Research and Development Investments

  • Companies are investing heavily in research and development to develop new and improved methotrexate products. This investment is crucial for maintaining market competitiveness and driving innovation[1].

Challenges and Restraints

Pricing and Reimbursement Policies

  • The availability and cost of methotrexate injections are major restraining factors. Pricing and reimbursement policies, which vary by country, can make it difficult for manufacturers to enter the market and gain traction[1].

Competitive Landscape

  • The competition in the methotrexate market is expected to intensify due to increasing demand and the entry of new players. This competition is driving companies to invest more in research and development to stay competitive[1].

Key Takeaways

  • The methotrexate drug market is expected to grow significantly, driven by the increasing prevalence of target diseases, technological advancements, and an aging population.
  • The market is segmented based on indication, drug type, drug form, route of administration, and distribution channel.
  • Regional markets, particularly in the U.S., China, Japan, and South Korea, are expected to show robust growth.
  • Companies are investing heavily in research and development to maintain competitiveness.
  • Pricing and reimbursement policies remain a significant challenge for market growth.

FAQs

Q: What is the projected market size of the methotrexate drug market by 2034?

A: The methotrexate drug market is projected to reach USD 1,058 million by 2034[1].

Q: What are the key drivers of the methotrexate market growth?

A: The key drivers include the increasing prevalence of target diseases, technological advancements, an aging population, and rising healthcare expenditure[3][4].

Q: Which segment of the methotrexate market is expected to show robust growth?

A: The cancer segment is forecasted to show robust growth, reaching USD 263.4 million by 2032[3].

Q: What are the major challenges facing the methotrexate market?

A: The major challenges include pricing and reimbursement policies, which vary by country and can restrict market access[1].

Q: Which regions are expected to witness significant growth in the methotrexate market?

A: The U.S., China, Japan, and South Korea are expected to witness significant growth in the methotrexate market[1].

Sources

  1. Future Market Insights: Methotrexate Drug Market Size, Share, Trends & Forecast by 2034.
  2. Cumberland Pharmaceuticals: Cumberland Pharmaceuticals Reports Third Quarter 2021 Financial Results & Company Update.
  3. Global Market Insights: Methotrexate Drugs Market Size & Share Report, 2024 – 2032.
  4. Market Research Intellect: Methotrexate Drugs Market Size, Share & Growth by 2031.
  5. Data Bridge Market Research: Methotrexate Injection Market Size, Value & Opportunities By 2030.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.